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Abstract: We present a case of leptomeningeal metastases in a 30-year-old man with an extragonadal germ cell tumor. The 
patient was referred to our hospital for treatment of an occipital brain metastasis. This lesion was resected, followed by 
whole brain radiotherapy and further chemotherapy, and a temporary complete remission was achieved. However, 
leptomeningeal recurrence developed, and despite salvage chemotherapy, the patient died of disease. Although multidisci-
plinary treatment is given to treat brain metastases of germ cell tumors, the patients’ prognosis has been unsatisfactory. The 
identiﬁ  cation of a standard/effective treatment is required.
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Introduction
Extragonadal germ cell tumors (GCTs) belong to poor prognosis, according to the International Germ 
Cell Consensus Classiﬁ  cation (IGCCC), and the presence of brain metastasis is predictive to worse 
prognosis. Recently, multidisciplinary approaches involving combination chemotherapy, irradiation, 
and surgery have been used to treat patients with brain metastasis, and successful cases have been 
reported (Bokemeyer et al. 1997; Fossa et al. 1999; Mahalati et al. 1999; Lutterbach et al. 2002). 
However, the long-term survival of such patients is not yet satisfactory. Intrathecal metastasis 
(meningeal dissemination) of GCT is rare, and no effective treatment has been established. We pres-
ent a case that temporarily responded to chemotherapy and discuss the possible treatment options in 
such cases.
Case Report
A 30-year-old man with an extragonadal GCT of mediastinal origin complained of right homonymous 
hemianopia and was referred to Shinshu University Hospital for the treatment of the brain metastasis. 
About 4 months earlier, the patient had received induction chemotherapy with three courses of BEP 
(bleomycin, etoposide, and cisplatin) for multiple lung metastases in another hospital. The brain lesion 
had grown rapidly (Fig. 1), and serum tumor markers were elevated, including lactate dehydrogenase 
(LDH) at 447 U/l (normal, 118–236), αfetoprotein (AFP) at 480 ng/ml (normal 10), and human cho-
rionic gonadotropin (HCG) at 629 IU/l (normal 1.0). The patient had immediate neurosurgery to 
remove the tumor. On pathology, the tumor was diagnosed as metastatic embryonal carcinoma and yolk 
sac tumor (Fig. 2). The patient also received whole brain radiation therapy (WBRT) (total 30 Gy/10 
fractions) and adjuvant chemotherapy consisting of two courses of VIP therapy (etoposide, ifosfamide, 
and cisplatin). All tumor markers normalized. The residual lung tumors were resected, and no tumor 
remnant was seen on pathology.
One month after lung surgery, the patient developed lumbago and a gait disturbance. On magnetic 
resonance imaging (MRI), multiple leptomeningeal metastases with no brain recurrence were seen 
(Fig. 3A). Salvage chemotherapy, consisting of combination irinotecan and nedaplatin therapy, was 
given. After four courses of therapy, the leptomeningeal lesions disappeared (Fig. 3B). However, the 
serum HCG elevated again, and recurrent cerebral ventricular and meningeal lesions appeared within 
a short period of time. Despite the use of additional salvage chemotherapy involving three courses 372
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of TIN therapy (paclitaxel, ifosfamide, and 
nedaplatin), in combination with the peripheral 
blood stem cell transplantation, the patient died 
due to disease progression 12 months after the 
initial brain surgery.
Discussion
Brain metastasis from malignant GCT occurs in 
1%–3% of patients (Bokemeyer et al. 1997; Fossa 
et al. 1999). Multidisciplinary treatment, involving 
chemotherapy, irradiation, and surgery, is required 
to treat brain GCT metastases. The prognosis of 
patients with brain metastasis is poor, but it is 
relatively better in patients with a solitary (isolated) 
metastasis and in those with an initial metastasis 
compared to patients with multiple lesions or a 
relapse (Bokemeyer et al. 1997; Fossa et al. 1999; 
Mahalati et al. 1999; Lutterbach et al. 2002). Fossa 
et al. reported that the 5-year survival rate of 
patients with an initial metastasis was 45%, but 
that of patients with recurrence after induction 
chemotherapy was 12% (Fossa et al. 1999). 
According to guidelines of the American National 
Cancer Institute (NCI) and the European Urologi-
cal Association, the standard treatment for GCT 
brain metastasis is chemotherapy in conjunction 
with WBRT (NCI, 2008; Albers et al. 2005). On 
the other hand, Salvati et al. recommended that, if 
the brain tumor is resectable, aggressive surgical 
treatment followed by WBRT and/or adjuvant 
chemotherapy should be given (Salvati et al. 
2006).
The incidence of leptomeningeal metastasis of 
primary central nervous system (CNS) tumors has 
been reported to range from 7% to 27%, but extra-
CNS GCT metastasis is rare (Engelhard et al. 
2005). There has been only one report in the last 
10 years (Miranda et al. 2005). The etiology of 
leptomeningeal metastasis has been considered to 
due to cerebrospinal ﬂ  uid (CSF) dissemination by 
direct contact with the tumor or by surgical inocu-
lation (Engelhard et al. 2005). The treatment of 
leptomeningeal metastasis is difﬁ  cult. Intrathecal 
injection of anti-cancer drugs such as methotrexate 
has been reported, but the effectiveness of this 
treatment in GCT is not proven (Engelhard et al. 
2005). Peereboom examined the brain capillary 
permeability of anti-cancer agents and reported 
that etoposide, cisplatin, irinotecan, and bleomycin 
had intermediate permeability, and that the com-
bination of these drugs might have some effect 
(Peereboom, 2005). Jahnke et al. reported the 
efﬁ  cacy of intraarterial chemotherapy in conjunc-
tion with transient osmotic blood brain barrier 
disruption for primary CNS germ cell tumors 
(Jahnke et al. 2007). However, long-term survivors 
without progression had been observed only in 
patients with pure germinoma. Recently, the efﬁ  -
cacy of new anti-cancer agents, such as paclitaxel, 
gemcitabin, oxaliplatin, and irinotecan, as well as 
the combination of these drugs, has been reported 
for cisplatin refractory disease, and their use is 
Figure 1. Brain MRI. The solitary metastatic lesion was shown, which 
was 4.5 cm × 3 cm in diameter, occupying the left occipital lobe 
(before operation).
Figure 2. H&E staining showed solid and tubular tumor cells with large, 
bizarre nuclei, coexisted with hemorrhage (magniﬁ  cation, × 100). Immuno-
histochemical staining showed tumor cells to be positive with CD30 and AFP 
that suggested the embryonal carcinoma with yolk sac tumor component, 
and partially positive with HCG, suggesting syncytiotrophoblastic cells.373
Leptomeningeal metastasis of germ cell tumor
Clinical Medicine: Oncology 2008:2 
expected to improve the prognosis (Kollmanns-
berger et al. 2006). Various combinations have 
been used, including irinotecan with nedaplatin (or 
cisplatin), TIN, or TIP (paclitaxel, ifosfamide, and 
cisplatin) (Miki et al. 2002; Nonomura et al. 
2007).
In the present case, these regimens were applied 
as salvage chemotherapy, and nedaplatin was 
selected instead of cisplatin, that had been used in 
previous therapies. Although the tumor initially 
responded well, recurrence occurred within a short 
period of time, and it became difﬁ  cult to continue 
chemotherapy because of adverse effects and 
impairment of the patient’s performance status. 
Brain surgery was initially done due to rapid tumor 
growth and the risk of brain hemorrhage. The role 
of adjuvant WBRT after surgery remains to be 
clariﬁ  ed. In general, conventional fractionation 
(viz. 2 Gy/fractions to 40 Gy) is usually recom-
mended for brain metastasis in order to decrease 
late neurotoxicity (Sofﬁ  etti et al. 2006). Despite 
the use of postoperative adjuvant therapy, intrathe-
cal metastases developed. Craniospinal radio-
therapy should be identiﬁ  ed as another treatment 
option for meningeal metastases. However, it 
might be difﬁ  cult to deliver in the context of myelo-
suppression from heavy pre-treatment with 
chemotherapy in the present case. If another che-
motherapy regimen including new anti-cancer 
drugs had been used as second-line therapy, or if 
a greater number of chemotherapy courses had 
been given after the brain surgery, the result might 
have been different.
Further clinical studies and the establishment 
of a management strategy for CNS metastasis in 
GCT patients are required.
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